Cargando…
Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity
Induction of selective, autoantigen-specific tolerance is the “holy grail” for the treatment and prevention of autoimmune diseases. Despite successes in many differential murine models, rational and efficient translation to the clinic has been difficult. During the 5th Annual Federation of Clinical...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213225/ https://www.ncbi.nlm.nih.gov/pubmed/16275758 http://dx.doi.org/10.1084/jem.20051224 |
_version_ | 1782148851718684672 |
---|---|
author | von Herrath, Matthias G. Nepom, Gerald T. |
author_facet | von Herrath, Matthias G. Nepom, Gerald T. |
author_sort | von Herrath, Matthias G. |
collection | PubMed |
description | Induction of selective, autoantigen-specific tolerance is the “holy grail” for the treatment and prevention of autoimmune diseases. Despite successes in many differential murine models, rational and efficient translation to the clinic has been difficult. During the 5th Annual Federation of Clinical Immunological Societies (FOCIS) Meeting, May 12–16, 2005, in Boston, MA, a Kirin-sponsored “Ideashop” was convened to discuss this theme amongst scientists, clinicians, industry partners, and funding agencies. |
format | Text |
id | pubmed-2213225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-22132252008-03-11 Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity von Herrath, Matthias G. Nepom, Gerald T. J Exp Med Meeting Review Induction of selective, autoantigen-specific tolerance is the “holy grail” for the treatment and prevention of autoimmune diseases. Despite successes in many differential murine models, rational and efficient translation to the clinic has been difficult. During the 5th Annual Federation of Clinical Immunological Societies (FOCIS) Meeting, May 12–16, 2005, in Boston, MA, a Kirin-sponsored “Ideashop” was convened to discuss this theme amongst scientists, clinicians, industry partners, and funding agencies. The Rockefeller University Press 2005-11-07 /pmc/articles/PMC2213225/ /pubmed/16275758 http://dx.doi.org/10.1084/jem.20051224 Text en Copyright © 2005, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Meeting Review von Herrath, Matthias G. Nepom, Gerald T. Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity |
title | Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity |
title_full | Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity |
title_fullStr | Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity |
title_full_unstemmed | Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity |
title_short | Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity |
title_sort | lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity |
topic | Meeting Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2213225/ https://www.ncbi.nlm.nih.gov/pubmed/16275758 http://dx.doi.org/10.1084/jem.20051224 |
work_keys_str_mv | AT vonherrathmatthiasg lostintranslationbarrierstoimplementingclinicalimmunotherapeuticsforautoimmunity AT nepomgeraldt lostintranslationbarrierstoimplementingclinicalimmunotherapeuticsforautoimmunity |